PMCF Study to Evaluate Efficacy, Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects

Last updated: June 15, 2023
Sponsor: Occlutech International AB
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heart Defect

Treatment

N/A

Clinical Study ID

NCT05264753
Occ2020_03
  • All Genders

Study Summary

This is a retrospective and prospective, multi-center, international, post marketing follow-up study to evaluate the safety and efficacy of the Occlutech PDA by using Occlutech Occlusions-Pusher (OOP) in patients with patent ductus arteriosus defects.

Efficacy and safety of implanted device(s) will be evaluated by vital signs, ECGs, and echocardiography data on baseline/implantation visit (include assessments within 36 hrs. post-procedure), Day 30 to Day 90, 6 months to 1 year, 2 years to 3 years after implantation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • A patient of any age will be eligible for PDA closure if he or she meets theindication and area of application as laid down in the IFU. Thus, the Occlutech PDAOccluder is intended for the non-surgical occlusion of Patent Ductus Arteriosus (PDA).

Exclusion

Exclusion Criteria:

  • Contraindications as laid down in the IFU:
  • Silent ductus or serious pulmonary hypertension:
  • Pulmonary Vascular Resistance (PVR) > 8 Wood Units
  • Presence of a known coagulation disorder
  • Thrombus at the position allocated for the implantation
  • A vein thrombosis in the blood vessels chosen for the introducing system
  • An active infection (active endocarditis or other infections causing bacteremia) orhistory of endocarditis within 3 months from the procedure.
  • Nitinol intolerance (nickel or titanium)
  • Contrast medium intolerance
  • Patients who have a vascular system (which is used to access the defect) that is toosmall to admit the required sheath

Study Design

Total Participants: 255
Study Start date:
December 20, 2021
Estimated Completion Date:
November 25, 2026

Study Description

Indication The Occlutech PDA Occluder is an occlusion system, which is percutaneously implanted through a catheter intervention technique and intended for the non-surgical occlusion of Patent Ductus Arteriosus (PDA) .Occlutech Occlusions-Pusher (OOP) and Occlutech Delivery Set (ODS) are recommended as delivery systems.

Study purpose This study aims to evaluate the safety and efficacy of The Occlutech PDA Occluder devices in patients with patent ductus arteriosus defects (PDA).

Study design This is a retrospective and prospective, multi-center, international, post marketing follow-up study to evaluate the safety and efficacy of the Occlutech® PDA occlude in subjects with patent ductus arteriosus defects.

Efficacy and safety of implanted device(s) will be evaluated by vital signs, ECGs, and echocardiography data on baseline/implantation visit (include assessments within 36 hrs. post-procedure), Day 30 to Day 90, 6 months to 1 year, 2 years to 3 years after implantation.

A sample size of N = 217 evaluable subjects will allow to estimate a proportion of ≤10% (or ≥90%) with precision of 4% at an alpha level of 5%. I.e., the total width of the two-sided 95%-confidence interval will be ≤8%.

Accounting for an anticipated, maximum drop-out (e.g., patients being not evaluable for the primary endpoints due to missing follow-up) rate of 15%, a total number of 255 subjects needs to be enrolled. Besides, N=217 evaluable patients guarantee two-sided 95%-CIs for continuous variables' means having a width of ~0.27 standard deviations (SD). This precision is sufficient for the descriptive objectives.

255 subjects treated for the non-surgical occlusion of PDA with the Occlutech® PDA Occluder. One should note that the majority (~ 90%) of the subjects will be children of young age (0-10 years).

Study objectives To evaluate the safety of the Occlutech® PDA Occluder in subjects requiring transcatheter occlusion (closure) of Patent Ductus Arteriosus.

To evaluate the efficacy of the Occlutech® PDA Occluder in subjects requiring transcatheter occlusion (closure) of Patent Ductus Arteriosus.

Connect with a study center

  • Ospedale Pediatrico Bambin Gesù

    Roma, 00146
    Italy

    Site Not Available

  • Rawalpindi Institute of Cardiology

    Rawalpindi,
    Pakistan

    Active - Recruiting

  • Military Hospital

    Tunis,
    Tunisia

    Active - Recruiting

  • Aydın Adnan Menderes University Hospital

    Aydın, Efeler
    Turkey

    Active - Recruiting

  • Dicle University Hospital

    Diyarbakır, SUR
    Turkey

    Active - Recruiting

  • Çukurova University Hospital

    Adana, Sarıçam
    Turkey

    Active - Recruiting

  • Eskişehir Osmangazi University Hospital

    Eskişehir, 26040
    Turkey

    Active - Recruiting

  • Royal Brompton & Harefield Hospitals

    London, SW3 6NP
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.